Literature DB >> 28722170

Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells.

Uri Rozovski1,2,3, David M Harris1, Ping Li1, Zhiming Liu1, Preetesh Jain1, Ivo Veletic1, Alessandra Ferrajoli1, Jan Burger1, Philip Thompson1, Nitin Jain1, William Wierda1, Michael J Keating1, Zeev Estrov1.   

Abstract

In chronic lymphocytic leukemia (CLL) cells, both interleukin-6 (IL-6) and the B-cell receptor (BCR) activate Janus kinase 2 (JAK2) and induce the phosphorylation of signal transduction and activator of transcription 3 (STAT3) on tyrosine 705 residues. However, whereas IL-6 phosphorylates STAT3 within 15 min, stimulation of the BCR with anti-immunoglobulin M (IgM) antibodies phosphorylates STAT3 in 2-4 hr. Here, we show that this process takes longer because it requires transcriptional activity of NF-κB. Using an electromobility shift assay, we found that incubation with IgM antibodies for 4 or 18 hr, but not 15 min, increased NF-κB DNA-binding of CLL cells and increased binding was translated to increased transcriptional activity. Hence, 42% of the 83 NF-κB target genes were constitutively expressed in all CLL cells prior to any inducible stimuli. However, activation of the BCR increased the number of NF-κB target genes with detectable expression by 23%. Remarkably, prolonged incubation with anti-IgM antibodies induced a time-dependent transcription, production and secretion of IL-6 protein. The IgM-induced production of IL-6 prompted the phosphorylation of STAT3 on tyrosine residues. This effect was inhibited by the JAK1/2 inhibitor of the JAK/STAT3 pathway ruxolitinib. Taken together, these results suggest that in CLL cells, constitutive tonic activation of NF-κB can be further enhanced by the BCR and that the BCR-induced activation of the JAK/STAT3 pathway depends on the NF-κB induced production of IL-6.
© 2017 UICC.

Entities:  

Keywords:  chronic lymphocytic Leukemia; nuclear factor κB; phosphorylation; signal transducer and activator of transcription 3

Mesh:

Substances:

Year:  2017        PMID: 28722170      PMCID: PMC5749978          DOI: 10.1002/ijc.30892

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

Review 2.  NF-kappaB as a therapeutic target in chronic lymphocytic leukemia.

Authors:  Monica Lopez-Guerra; Dolors Colomer
Journal:  Expert Opin Ther Targets       Date:  2010-03       Impact factor: 6.902

3.  Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells.

Authors:  Uri Rozovski; Srdana Grgurevic; Carlos Bueso-Ramos; David M Harris; Ping Li; Zhiming Liu; Ji Yuan Wu; Preetesh Jain; William Wierda; Jan Burger; Susan O'Brien; Nitin Jain; Alessandra Ferrajoli; Michael J Keating; Zeev Estrov
Journal:  Mol Cancer Res       Date:  2015-03-02       Impact factor: 5.852

4.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 5.  The interleukin-8 pathway in cancer.

Authors:  David J J Waugh; Catherine Wilson
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

6.  Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy.

Authors:  Marta Muzio; Benedetta Apollonio; Cristina Scielzo; Michela Frenquelli; Irene Vandoni; Vassiliki Boussiotis; Federico Caligaris-Cappio; Paolo Ghia
Journal:  Blood       Date:  2008-02-21       Impact factor: 22.113

7.  A Sleeping Beauty screen reveals NF-kB activation in CLL mouse model.

Authors:  Nicola Zanesi; Veronica Balatti; Jesse Riordan; Aaron Burch; Lara Rizzotto; Alexey Palamarchuk; Luciano Cascione; Alessandro Lagana; Adam J Dupuy; Carlo M Croce; Yuri Pekarsky
Journal:  Blood       Date:  2013-04-16       Impact factor: 22.113

8.  STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.

Authors:  Yuxin Wang; Anette H H van Boxel-Dezaire; HyeonJoo Cheon; Jinbo Yang; George R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

9.  Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.

Authors:  T Robak; A Wierzbowska; M Błasińska-Morawiec; A Korycka; J Z Błoński
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

10.  Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia.

Authors:  Ping Li; Srdana Grgurevic; Zhiming Liu; David Harris; Uri Rozovski; George A Calin; Michael J Keating; Zeev Estrov
Journal:  PLoS One       Date:  2013-06-04       Impact factor: 3.240

View more
  10 in total

1.  Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.

Authors:  Francesca Arruga; Valeria Bracciamà; Nicoletta Vitale; Tiziana Vaisitti; Katiuscia Gizzi; Alison Yeomans; Marta Coscia; Giovanni D'Arena; Gianluca Gaidano; John N Allan; Richard R Furman; Graham Packham; Francesco Forconi; Silvia Deaglio
Journal:  Leukemia       Date:  2019-08-29       Impact factor: 11.528

2.  Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.

Authors:  Yun Chen; Liguang Chen; Jian Yu; Emanuela M Ghia; Michael Y Choi; Ling Zhang; Suping Zhang; Elsa Sanchez-Lopez; George F Widhopf; Karen Messer; Laura Z Rassenti; Catriona Jamieson; Thomas J Kipps
Journal:  Blood       Date:  2019-08-13       Impact factor: 22.113

Review 3.  Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution.

Authors:  Uddalak Bharadwaj; Moses M Kasembeli; Prema Robinson; David J Tweardy
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

4.  Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia.

Authors:  Hua-Qing Wang; Li Jia; Yu-Ting Li; Timothy Farren; Samir G Agrawal; Feng-Ting Liu
Journal:  J Cell Physiol       Date:  2019-01-08       Impact factor: 6.384

5.  STAT3 promotes chronic lymphocytic leukemia progression through upregulating SMYD3 expression.

Authors:  Wei Ma; Yingying Zhang; Yu Qi; Shidong Guo
Journal:  Arch Med Sci       Date:  2018-08-23       Impact factor: 3.318

6.  HELQ and EGR3 expression correlate with IGHV mutation status and prognosis in chronic lymphocytic leukemia.

Authors:  Chao Guo; Ya-Yue Gao; Qian-Qian Ju; Chun-Xia Zhang; Ming Gong; Zhen-Ling Li
Journal:  J Transl Med       Date:  2021-01-23       Impact factor: 5.531

7.  miR-29b-3p suppresses the malignant biological behaviors of AML cells via inhibiting NF-κB and JAK/STAT signaling pathways by targeting HuR.

Authors:  Yong-Jing Tang; Wei Wu; Qiao-Qian Chen; Shu-Han Liu; Zhi-Yuan Zheng; Zhao-Lei Cui; Jian-Ping Xu; Yan Xue; Dong-Hong Lin
Journal:  BMC Cancer       Date:  2022-08-20       Impact factor: 4.638

8.  The Pt(S-pr-thiosal)2 and BCL1 Leukemia Lymphoma: Antitumor Activity In Vitro and In Vivo.

Authors:  Zana Besser Silconi; Vesna Rosic; Sasa Benazic; Gordana Radosavljevic; Marina Mijajlovic; Jelena Pantic; Zoran R Ratkovic; Gordana Radic; Aleksandar Arsenijevic; Marija Milovanovic; Nebojsa Arsenijevic; Jelena Milovanovic
Journal:  Int J Mol Sci       Date:  2022-07-24       Impact factor: 6.208

9.  The Antidiabetic and Antinephritic Activities of Tuber melanosporum via Modulation of Nrf2-Mediated Oxidative Stress in the db/db Mouse.

Authors:  Xue Jiang; Shanshan Teng; Xue Wang; Shan Li; Yaqin Zhang; Di Wang
Journal:  Oxid Med Cell Longev       Date:  2018-07-29       Impact factor: 6.543

10.  Shikonin Derivatives from Onsoma visianii Decrease Expression of Phosphorylated STAT3 in Leukemia Cells and Exert Antitumor Activity.

Authors:  Zeljko Todorovic; Jelena Milovanovic; Dragana Arsenijevic; Nenad Vukovic; Milena Vukic; Aleksandar Arsenijevic; Predrag Djurdjevic; Marija Milovanovic; Nebojsa Arsenijevic
Journal:  Nutrients       Date:  2021-03-31       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.